Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073840 · ClinicalTrials.gov registry record · Phase 3
Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma
A Phase 3 study of Asthma, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 386
- Enrollment target
- 20
- Study locations
NCT00073840: Completed Phase 3 study of Asthma, sponsored by Sumitomo Pharma America.
NCT00073840 is a Phase 3 study of Asthma that has completed, run by Sumitomo Pharma America. The registered enrollment target is 386 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00073840, a Phase 3 study of Asthma, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 386 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to investigate the efficacy of levalbuterol 90 ug (2 actuations, 45 ug each) versus placebo (2 actuations) in the treatment and prevention of bronchoconstriction in adolescent and adult subjects with asthma, with all treatments administered 4 times a day (QID).
Conditions Studied
Interventions
- DRUG levalbuterol
Study Locations (20)
California
- Integrated Research Group - Corona
- Radiant Research, Inc. - Encinitas
- Allergy & Asthma Specialists Medical Group - Huntington Beach
- Asthma, Allergy & Respiratory Care Center - Long Beach
- Allergy Research Foundation, Inc. - Los Angeles
- Madera Family Medical Group - Madera
- Southern California Research - Mission Viejo
- Comprehensive Allergy Services - Oakland
- Clinical Trials of Orange County - Orange
- Allergy Associates Medical Group - San Diego
- Allergy & Asthma Medical Group & Research Center - San Diego
- Allergy & Asthma Assoc. of Santa Clara Valley Research Center - San Jose
- West Coast Clinical Trials - Signal Hill
- Allergy & Asthma Medical Group of Diablo Valley, Inc. - Walnut Creek
Georgia
- Watts Medical Research - Barnesville
- The Allergy & Asthma Clinical Research Center - Conyers
- Aeroallergy Research Laboratories of Savannah, Inc. - Savannah
Alabama
- Allergy & Asthma Center, LLC - Oxford
Arizona
- Alta Clinical Research - Tucson
Colorado
- 1st Allergy & Asthma Clinical Research Ctr - Thornton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 386 participants |
| Start Date | 2002-12 |
| Est. Completion | 2003-06 |
| Phase | Phase 3 |
What the finished NCT00073840 record still lists
NCT00073840 is an interventional study that assigns participants to a tested intervention. The registered 386 participants enrollment target is mid-sized for trials with a published cap, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which levalbuterol is the first listed.
NCT00073840 names 20 study sites across 5 states, led by California, Georgia, Alabama.
Frequently Asked Questions
What is clinical trial NCT00073840 about?
NCT00073840 is a clinical study titled "Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma". The primary objective of this study is to investigate the efficacy of levalbuterol 90 ug (2 actuations, 45 ug each) versus placebo (2 actuations) in the treatment and prevention of bronchoconstriction in adolescent and adult subjects with asthma, with all treatments administered 4 times a day (QID).
What is the current status of trial NCT00073840?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 386 participants. The study started on 2002-12. Estimated completion is 2003-06.
What conditions does trial NCT00073840 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00073840?
The interventions under investigation include: levalbuterol (DRUG).
Who is sponsoring clinical trial NCT00073840?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00073840 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00073840's enrollment target sits among peer trials
386 99th of 374 higher than 275 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05645107 · 386 participants · Phase 3
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- NCT05896189 · 386 participants · NA
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
- NCT06686121 · 386 participants · Phase 3
Improving Mobility After Revascularization in Peripheral Artery Disease
- NCT07424547 · 386 participants · Phase 1
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia